236 related articles for article (PubMed ID: 38174191)
21. Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD - Reconciling the present with the past.
Ayonrinde OT
JHEP Rep; 2021 Jun; 3(3):100261. PubMed ID: 34036255
[TBL] [Abstract][Full Text] [Related]
22. Pediatric non-alcoholic fatty liver disease: an increasing public health issue.
Berardis S; Sokal E
Eur J Pediatr; 2014 Feb; 173(2):131-9. PubMed ID: 24068459
[TBL] [Abstract][Full Text] [Related]
23. Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease.
Seif El Dahan K; Daher D; Singal AG
Clin Mol Hepatol; 2023 Feb; 29(Suppl):S207-S219. PubMed ID: 36103899
[TBL] [Abstract][Full Text] [Related]
24. Non-alcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes, and Non-viral Hepatocarcinoma: Pathophysiological Mechanisms and New Therapeutic Strategies.
Vetrano E; Rinaldi L; Mormone A; Giorgione C; Galiero R; Caturano A; Nevola R; Marfella R; Sasso FC
Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831004
[TBL] [Abstract][Full Text] [Related]
25. Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges.
Ahmad MI; Khan MU; Kodali S; Shetty A; Bell SM; Victor D
J Hepatocell Carcinoma; 2022; 9():477-496. PubMed ID: 35673598
[TBL] [Abstract][Full Text] [Related]
26. Obesity, non-alcoholic fatty liver disease and hepatocellular carcinoma: current status and therapeutic targets.
Chen Y; Wang W; Morgan MP; Robson T; Annett S
Front Endocrinol (Lausanne); 2023; 14():1148934. PubMed ID: 37361533
[TBL] [Abstract][Full Text] [Related]
27. Current Concepts, Opportunities, and Challenges of Gut Microbiome-Based Personalized Medicine in Nonalcoholic Fatty Liver Disease.
Sharpton SR; Schnabl B; Knight R; Loomba R
Cell Metab; 2021 Jan; 33(1):21-32. PubMed ID: 33296678
[TBL] [Abstract][Full Text] [Related]
28. The immune response as a therapeutic target in non-alcoholic fatty liver disease.
Ortiz-López N; Fuenzalida C; Dufeu MS; Pinto-León A; Escobar A; Poniachik J; Roblero JP; Valenzuela-Pérez L; Beltrán CJ
Front Immunol; 2022; 13():954869. PubMed ID: 36300120
[TBL] [Abstract][Full Text] [Related]
29. Non-invasive diagnosis and staging of non-alcoholic fatty liver disease.
Kechagias S; Ekstedt M; Simonsson C; Nasr P
Hormones (Athens); 2022 Sep; 21(3):349-368. PubMed ID: 35661987
[TBL] [Abstract][Full Text] [Related]
30. Pediatric non-alcoholic fatty liver disease: New insights and future directions.
Marzuillo P; Del Giudice EM; Santoro N
World J Hepatol; 2014 Apr; 6(4):217-25. PubMed ID: 24799990
[TBL] [Abstract][Full Text] [Related]
31. Current and Emerging Biomarkers and Imaging Modalities for Nonalcoholic Fatty Liver Disease: Clinical and Research Applications.
Hydes T; Brown E; Hamid A; Bateman AC; Cuthbertson DJ
Clin Ther; 2021 Sep; 43(9):1505-1522. PubMed ID: 34400007
[TBL] [Abstract][Full Text] [Related]
32. Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease.
Bertot LC; Adams LA
Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):179-187. PubMed ID: 30791782
[TBL] [Abstract][Full Text] [Related]
33. Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease.
Wong CR; Njei B; Nguyen MH; Nguyen A; Lim JK
Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1061-1069. PubMed ID: 28960360
[TBL] [Abstract][Full Text] [Related]
34. The epidemiology of non-alcoholic fatty liver disease.
Bellentani S
Liver Int; 2017 Jan; 37 Suppl 1():81-84. PubMed ID: 28052624
[TBL] [Abstract][Full Text] [Related]
35. Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians.
Geh D; Manas DM; Reeves HL
Hepatobiliary Surg Nutr; 2021 Jan; 10(1):59-75. PubMed ID: 33575290
[TBL] [Abstract][Full Text] [Related]
36. Management of NAFLD patients with advanced fibrosis.
Maya-Miles D; Ampuero J; Gallego-Durán R; Dingianna P; Romero-Gómez M
Liver Int; 2021 Jun; 41 Suppl 1():95-104. PubMed ID: 34155801
[TBL] [Abstract][Full Text] [Related]
37. Histone Modifications in NAFLD: Mechanisms and Potential Therapy.
Shi Y; Qi W
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834101
[TBL] [Abstract][Full Text] [Related]
38. Circulating MicroRNAs: Diagnostic Value as Biomarkers in the Detection of Non-alcoholic Fatty Liver Diseases and Hepatocellular Carcinoma.
Rana M; Saini M; Das R; Gupta S; Joshi T; Mehta DK
Microrna; 2023; 12(2):99-113. PubMed ID: 37005546
[TBL] [Abstract][Full Text] [Related]
39. Low HDL-cholesterol levels predict hepatocellular carcinoma development in individuals with liver fibrosis.
Crudele L; De Matteis C; Piccinin E; Gadaleta RM; Cariello M; Di Buduo E; Piazzolla G; Suppressa P; Berardi E; Sabbà C; Moschetta A
JHEP Rep; 2023 Jan; 5(1):100627. PubMed ID: 36561127
[TBL] [Abstract][Full Text] [Related]
40. Current Challenges and Future Direction in Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.
Cholankeril G; El-Serag HB
Semin Liver Dis; 2023 Feb; 43(1):89-99. PubMed ID: 36216350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
